osteoclasts are able to enhance growth and survival of MM cells under cell-to-cell interactions with MM cells.
Recently, several groups have reported independently, an acquired somatic point mutation in the JAK2 gene (V617F) in approximately 90% of patients with polycythaemia vera, as well as nearly half of patients with idiopathic myelofibrosis and essential thrombocytosis. [1] [2] [3] [4] In addition, some reports suggested that the V617F mutation is infrequent in myelodysplastic syndromes (MDS) (1-5%) and in acute myeloid leukemias (AML) (0% in AML without a history of chronic myeloproliferative disorder (CMPD), and 18% in AML M7). 2, 5, 6 However, CMPD and MDS can be difficult to classify, and cases with overlapping features between CMPD and MDS do exist, and should be included in the category of MDS/MPD recently defined in the new WHO classification. One of these borderline categories, in which the search for JAK2 mutations is of interest, is MDS/AML with fibrosis. In a recent issue of Leukemia, Ohyashiki et al., described the presence of JAK2 mutation in two of six MDS with fibrosis, but in none of the three cases each of AML, lymphoma, or chronic myeloid leukemia with fibrosis, nor in 38 cases of MDS without fibrosis. 7 The authors speculated, that either the JAK2 mutation is responsible for the development of secondary fibrosis in patients with MDS, or that cases exhibiting the JAK2 mutation rather represent CMPD with features of MDS, which should be categorized as MDS/MPD unclassifiable according to the WHO classification.
In order to answer this question, we analyzed 25 cases of MDS (n ¼ 17) and de novo AML (n ¼ 8) with fibrosis, 19 MDS (n ¼ 12) and de novo AML (n ¼ 7) without fibrosis, four cases of MDS/MPD unclassifiable, and 14 cases with reactive changes, for the presence of the JAK2 mutation. The group with fibrosis consisted of refractory cytopenia with multilineage dysplasia, (n ¼ 5); refractory anemia with excess of blasts (RAEB)-1, (n ¼ 2); RAEB-2, (n ¼ 10) and AML, (n ¼ 8), (M0, M5 (FAB), acute panmyelosis with myelofibrosis). Myelodysplastic syndromes with fibrosis was defined by peripheral blood, and bone marrow findings typical for MDS, including pancytopenia and dysplastic features in one ore more hematopoietic lineages and bone marrow fibrosis (Xgrade 2) in the absence of any signs of CMPD. Cytogenetic data were available in all but four cases, including þ 14, À7, del 13q, del 12p, del 5q, þ 8, t(2;10), del 20q and t(11;21) abnormalities. The presence of the V617F mutation was assessed on paraffin-embedded bone marrow trephine biopsies with two previously published strategies. 1, 4 The first approach represents an allele-specific multiplex PCR with one common reverse and two separate forward primers, one of them with a mismatch at the 3 0 -end specific for the Letters to the Editor mutated allele. In the case of a mutation, the PCR generates an additional 203 bp PCR product. 1 The second strategy consists of nested PCR, and subsequent restriction enzyme digestion with BsaXI (New England Biolabs, Hitchin, UK). In case of mutated DNA, the PCR product remains undigested, whereas unmutated DNA results in two fragments of 170 and 203 bp in size. 4 None of the MDS/AML cases showed evidence of the JAK2 V617F mutation, regardless of the presence or absence of fibrosis. Interestingly, the mutation was detected in three of four cases (75%) diagnosed as MDS/MPD. In contrast to the MDS/AML with fibrosis, these four patients showed some clinical features of chronic myeloproliferative disease, including splenomegaly, leukocytosis and/or thrombocytosis, as well as, morphological features of CMPD in the trephine biopsy. One of the positive cases was classified as atypical chronic myelogenous leukemia negative for BCR/ABL fusion transcripts.
In contrast to the results from Ohyashiki et al., our results inidicate that the JAK2 V617F mutation is exceedingly rare in bona fide MDS or de novo AML, regardless of the presence of fibrosis. Furthermore, the identification of the JAK2 mutation in MDS/MPD cases indicates that these cases are more closely related to classical CMPD. This interpretation is supported by other reports demonstrating the occurrence of the JAK2 mutation in MDS/MPD, such as chronic myelomonocytic leukemia, although the latter entity shows a lower incidence of JAK2 mutations than CMPD. 5, 6, 8, 9 We believe that the analysis of the JAK2 V617F mutation, in difficult-to-classify cases, will help to clarify the borderline between MDS, on one hand, and atypical CMPD and MDS/MPD on the other hand. The better understanding of these entities, potentially may lead in the near future to identify new therapeutic options for these patients. Bcl2 was identified as the cellular oncogene product associated with the t(14,18) translocation commonly seen in B-cell lymphomas and is the founding member of a family of proteins that regulate apoptosis. 1 Bcl2 protects cells from a wide range of stress challenges and thus high Bcl2 levels would be predicted to favor chemoresistance.
1,2 However, Bcl2 expression levels alone do not always correlate with poor prognosis (e.g. some acute myeloid leukemias (AML) patient subsets, pediatric acute lymphoblastic leukemia patients).
2 As Bcl2 expression alone cannot explain its full and potent antiapoptotic activity, other regulatory mechanisms must be involved.
The phosphorylation status of Bcl2 influences its function. [3] [4] [5] [6] Growth agonist-induced phosphorylation of Bcl2 at serine 70 is required for Bcl2's full and potent antiapoptotic function. [4] [5] [6] PKC a and extracellular signal-related kinase (ERK) have been identified as Bcl2 kinases that promote survival. 5, 6 In hematopoietic cell lines, overexpression of exogenous kinase or treatment of cells with kinase agonist (i.e. bryostatin for PKC a and aurintricarboxylic acid for ERK) results in enhanced Bcl2 phosphorylation and increased resistance to apoptosis on induction of stress challenges (i.e. IL-3 withdrawal or treatment of cells with chemotherapeutic agents). [5] [6] [7] Consequently, the phosphorylation status of Bcl2 in AML blast cells or any other human malignancy is unknown. Furthermore, the consequence of phosphorylated Bcl2 on the survival of AML blast cells has yet to be determined. In the present study, we investigate Bcl2 phosphorylation status using metabolic radiolabeling and activation status of PKC a and ERK in blast cells from AML patients and examine their effect on patient survival. We find that Bcl2 is phosphorylated in nearly half the AML blast cells tested. Furthermore, Bcl2 is always phosphorylated in AML blast cells with activated PKC a and ERK but never in cells that lack
